Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PAM | P19021 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14166378 | 0.97 | DGKA (0.67) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL4269367 | 0.97 | DGKA (0.67) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL19378376 | 0.90 | MAPT (0.58) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL8211006 | 0.89 | DGKA (0.57) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL326500 | 0.89 | DGKA (0.57) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL16062674 | 0.88 | DGKA (0.57) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL31126283 | 0.88 | DGKA (0.80) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL31493856 | 0.88 | DGKA (0.80) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL31126278 | 0.88 | DGKA (0.80) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL15130569 | 0.88 | DGKA (0.80) | DGKAMAPTPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054934-B1 | METHODS AND COMPOSITIONS FOR TREATING WITHDRAWAL SYNDROMES USING NON-SEDATIVE DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-10874642-B2 | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions | TEIKOKU PHARMA USA, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3054931-B1 | TRANSDERMAL DELIVERY DEVICE FOR MANAGING PAIN COMPRISING DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3054935-B1 | METHODS AND COMPOSITIONS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER, ANXIETY AND INSOMNIA USING DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3054932-B1 | DEXMEDETOMIDINE TRANSDERMAL DELIVERY DEVICES AND METHODS FOR USING THE SAME | TEIKOKU PHARMA USA INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3054930-B1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF A NON-SEDATIVE AMOUNT OF DEXMEDETOMIDINE | TEIKOKU PHARMA USA INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200093800-A1 | Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions | TEIKOKU PHARMA USA, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20180117012-A1 | Methods of Managing Pain Using Dexmedetomidine Transdermal Delivery Devices | TEIKOKU PHARMA USA, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20150098981-A1 | Methods and Compositions for Transdermal Delivery of a Non-Sedative Amount of Dexmedetomidine | TEIKOKU PHARMA USA, INC. | 2015-04-09 | — | — | US | disclosed |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | TEIKOKU PHARMA USA, INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874642-B2 | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions | ADRA2C, ADRA2A, DRD2 | DGKA 474/4885MAPT 191/4885PRSS1 4815/4885 |
| US-20180117012-A1 | Methods of Managing Pain Using Dexmedetomidine Transdermal Delivery Devices | OPRL1, OPRK1, AVPR2 | DGKA 698/4885MAPT 2110/4885PRSS1 4047/4885 |
| US-20150098981-A1 | Methods and Compositions for Transdermal Delivery of a Non-Sedative Amount of Dexmedetomidine | ADRA2C, ADRA2B, ADRA2A | DGKA 444/4885MAPT 1498/4885PRSS1 4798/4885 |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | CRH, OPRD1, ADRA2C | DGKA 338/4885MAPT 979/4885PRSS1 4168/4885 |
| US-20200093800-A1 | Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions | ADRA2C, ADRA2A, DRD2 | DGKA 474/4885MAPT 191/4885PRSS1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.